These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19470469)

  • 1. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
    Yan M; Myung SJ; Fink SP; Lawrence E; Lutterbaugh J; Yang P; Zhou X; Liu D; Rerko RM; Willis J; Dawson D; Tai HH; Barnholtz-Sloan JS; Newman RA; Bertagnolli MM; Markowitz SD
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9409-13. PubMed ID: 19470469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
    Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
    Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
    Myung SJ; Rerko RM; Yan M; Platzer P; Guda K; Dotson A; Lawrence E; Dannenberg AJ; Lovgren AK; Luo G; Pretlow TP; Newman RA; Willis J; Dawson D; Markowitz SD
    Proc Natl Acad Sci U S A; 2006 Aug; 103(32):12098-102. PubMed ID: 16880406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
    Wang J; Cho NL; Zauber AG; Hsu M; Dawson D; Srivastava A; Mitchell-Richards KA; Markowitz SD; Bertagnolli MM
    Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):728-736. PubMed ID: 29769213
    [No Abstract]   [Full Text] [Related]  

  • 5. Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
    Zhang B; Ma X; Li Z; Gao X; Wang F; Liu L; Shen G; Sang Y; Li M; Li Y; Zhao J; Wei Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):797-807. PubMed ID: 23385883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
    Yan M; Rerko RM; Platzer P; Dawson D; Willis J; Tong M; Lawrence E; Lutterbaugh J; Lu S; Willson JK; Luo G; Hensold J; Tai HH; Wilson K; Markowitz SD
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17468-73. PubMed ID: 15574495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
    Tai HH; Chi X; Tong M
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):37-40. PubMed ID: 21763448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
    Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C
    Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.
    Choi SH; Kim BG; Robinson J; Fink S; Yan M; Sporn MB; Markowitz SD; Letterio JJ
    J Clin Invest; 2014 Jun; 124(6):2472-82. PubMed ID: 24837432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
    Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
    Kaliberova LN; Kusmartsev SA; Krendelchtchikova V; Stockard CR; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Mol Cancer Ther; 2009 Nov; 8(11):3130-9. PubMed ID: 19887544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
    Fink SP; Yamauchi M; Nishihara R; Jung S; Kuchiba A; Wu K; Cho E; Giovannucci E; Fuchs CS; Ogino S; Markowitz SD; Chan AT
    Sci Transl Med; 2014 Apr; 6(233):233re2. PubMed ID: 24760190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
    Lee HJ; Yang DH; Ryu YM; Song M; Song HJ; Jung KW; Kim KJ; Ye BD; Byeon JS; Choi EK; Yang SK; Kim JH; Myung SJ
    J Korean Med Sci; 2013 Aug; 28(8):1154-60. PubMed ID: 23960441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention.
    Fink SP; Yang DH; Barnholtz-Sloan JS; Ryu YM; Mikkola D; Potter JD; Lampe JW; Markowitz SD; Myung SJ
    Dig Dis Sci; 2013 Sep; 58(9):2615-22. PubMed ID: 23625286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
    Mehdawi LM; Prasad CP; Ehrnström R; Andersson T; Sjölander A
    Mol Oncol; 2016 Nov; 10(9):1415-1429. PubMed ID: 27522468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase.
    Yao B; Xu J; Harris RC; Zhang MZ
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F433-9. PubMed ID: 18057186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.
    Dai L; King DW; Perera DS; Lubowski DZ; Burcher E; Liu L
    Dig Dis Sci; 2015 May; 60(5):1236-46. PubMed ID: 25666316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
    Chi X; Freeman BM; Tong M; Zhao Y; Tai HH
    Arch Biochem Biophys; 2009 Jul; 487(2):139-45. PubMed ID: 19501039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
    Mehdawi LM; Satapathy SR; Gustafsson A; Lundholm K; Alvarado-Kristensson M; Sjölander A
    Oncotarget; 2017 May; 8(21):35033-35047. PubMed ID: 28402256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.